摘要
[目的]评价2013—2019年河南省城市居民肝癌筛查的结果。[方法]采取整群抽样的方法,选取河南省40~74岁城市户籍居民进行癌症危险因素调查和肝癌风险评估,并对评估出的肝癌高危人群进行甲胎蛋白(AFP)联合超声检查。采用χ2检验分析不同组间人群的筛查参与率。[结果]本研究共招募36 781名当地肝癌高危人群为研究对象,年龄为(55.20±8.31)岁,男性占48.19%(17 725名);共有17 241名接受了肝癌筛查,总体参与率为46.87%。检出2例疑似肝癌,检出率为0.01%,检出肝占位164例,检出率为0.95%,检出肝硬化106例,检出率为0.61%,检出AFP阳性49例,检出率为0.28%,检出脂肪肝4 848例,检出率为28.12%。男性肝占位检出率(1.19%)均高于女性(0.76%)。[结论] AFP联合超声作为肝癌筛查的手段有助于早期发现肝癌病变。下一步应努力提高人群筛查参与率以及筛查提供方的组织实施和服务能力,提高筛查效益。
[Purpose] To analyze the results of liver cancer screening in urban areas of Henan Province from 2013 to 2019. [Methods] A cluster sampling method was used to select the residents of 40~74 years old in Henan Province to assess the liver cancer risk. Subjects with high risk of liver cancer received AFP test combined ultrasonography for liver cancer screening. Chi-square test was used to analyze the participation rate among different groups. [Results] A total of 36 781 residents aged(55.20 ± 8.31) years and with 48.19%(17 725) as males were identified as at high risk for liver cancer, among which 17 241 took the following liver cancer screening with a participation rate of 46.87%. Two cases of suspected liver cancer were detected with a detection rate of0.01%;164 cases of hepatic space occupying lesion were detected with a detection rate of 0.95%;106 cases of liver cirrhosis were detected, with a detection rate of 0.61%;49 cases of AFP positive were detected with a detection rate was 0.28%;and 4 848 cases of fatty liver were detected with a detection rate of 28.12%. The detection rate of hepatic space occupying lesion in men(1.19%) was higher than that in women(0.76%). [Conclusion] AFP test combined ultrasonography in screening for liver cancer is helpful for early detection of liver lesions. The participation rate of the population, the program implementation and service capabilities of the screening provider need to be further improved.
作者
郭兰伟
刘曙正
郑黎阳
郭晓霞
陈琼
曹小琴
孙喜斌
张韶凯
GUO Lan-wei;LIU Shu-zheng;ZHENG Li-yang;GUO Xiao-xia;CHEN Qiong;CAO Xiao-qin;SUN Xi-bin;ZHANG Shao-kai(Henan Office for Cancer Control and Research,Henan Engineering Research Center of Cancer Prevention and Control,Henan International Joint Laboratory of Cancer Prevention,The Affiliated Cancer Hospital of Zhengzhou University,Henan Cancer Hospital,Zhengzhou 450008,China;The Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital,Zhengzhou 450008,China)
出处
《中国肿瘤》
CAS
CSCD
北大核心
2021年第7期516-522,共7页
China Cancer
基金
河南省科技攻关计划(192102310353)
国家重大公共卫生服务专项—城市癌症早诊早治项目。
关键词
肝癌
甲胎蛋白
高危人群
筛查
河南
liver cancer
AFP
high risk population
screening
Henan